Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs EPAM Systems Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.67 (market cap $39.89B), while EPAM Systems Inc trades at $86.06 (market cap $4.38B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.1× EPAM Systems Inc's market cap. Which is the better fit depends on your goals.
| ALNY | EPAM | |
|---|---|---|
Market Cap | $39.89B | $4.38B |
Sector | Health | Technology |
52-Week High | $491.22 | $221.40 |
52-Week Low | $278.09 | $76.04 |
Enterprise Value | $38.15B | $3.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EPAM Systems trades at $83.89, down 3.9% in the last session, with a bearish technical signal from moving averages. The company maintains solid profitability with 29% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights EPAM's AI partnerships and upcoming Q2 2026 earnings release. Valuation metrics appear attractive with P/E of 12.05 and P/S of 0.84, well below sector averages.
The stock presents a compelling value opportunity with strong analyst support (65% buy ratings) and a $128.55 consensus price target representing 53% upside potential. Key risks include competitive pressures in IT services and recent net income margin compression from 9.61% in 2024 to 6.96% in 2025. The upcoming Q2 earnings report on July 6, 2026 will be critical for validating growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
